Survey of aspirin administration in systemic mastocytosis

Joseph H. Butterfield

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Background: Previous recommended doses for aspirin use in systemic mastocytosis have been 3.9-5.2 g/d. Here, the aspirin doses and biochemical responses of patients with systemic mastocytosis given aspirin to decrease prostaglandin D2 levels and prevent symptoms were reviewed. Methods: Twenty patients with systemic mastocytosis who had been given aspirin were identified, and their clinical and laboratory records were reviewed including changes in the excretion of the prostaglandin D2 metabolite 11β-prostaglandin F in response to aspirin. Results: Two of 20 patients developed either a delayed reaction or flushing during outpatient updosing with aspirin. In 20 of 20 patients with elevated baseline urinary excretion of 11β-prostaglandin F, aspirin therapy caused a reduction to normal levels of excretion. Doses of aspirin required ranged from 81 mg twice daily to 500 mg twice daily. Conclusions: Control of elevated prostaglandin D2 levels in systemic mastocytosis can be achieved with lower doses of aspirin than previously reported as necessary in this disorder.

Original languageEnglish (US)
Pages (from-to)122-124
Number of pages3
JournalProstaglandins and Other Lipid Mediators
Issue number3-4
StatePublished - Apr 1 2009


  • Aspirin
  • Prostaglandin D
  • Systemic mastocytosis

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology


Dive into the research topics of 'Survey of aspirin administration in systemic mastocytosis'. Together they form a unique fingerprint.

Cite this